Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I modified FOLFIRINOX plus concurrent radiation for unresectable/borderline resectable pancreatic cancer
jRCTs051220029Phase 1Recruiting
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC). Primary endpoint: Dose-limiting toxicity. Started May 2022; status: recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051220029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220029.